Get started
Quickstart
Once installation reports READY, start the platform:
livemore doctor # readiness check; the last line should read READY
livemore start # starts LIFE :8851, Aegle :8850 and Cendos :8852
livemore status # what is up
livemore open # opens the console in your browser
livemore programs list # what can and cannot run, and why
You should see:
LivemoreBio infrastructure
----------------------------------------------------
โ up LIFE :8851 20 diseases ยท 172 risk loci
โ up Aegle :8850 twin:
โ up Cendos :8852 in-silico assays ready
----------------------------------------------------
registry: /home/you/.livemore/registry.json (3 registered)
Each service has one job:
- Aegle (
:8850): the digital twins, and the console you look at. - LIFE (
:8851): the patch and continuous-measurement side. - Cendos (
:8852): the in-silico lab where experiments run.
Stop everything with livemore stop.
A new workspace
A fresh workspace starts with an unregistered healthy reference preview, not an admitted twin. That is deliberate: admitting a twin is a governed step with consent and a source class attached, and the installer does not do it for you.
Works immediately:
- all six reference programs, and their refusals;
- the genome-scale metabolic engine;
- in-silico assays (
assay metformin dose=1.0); - the console, the notebooks and every export.
Needs an admitted twin first:
- continuous execution and the LIFE Patch closed loop.
Asked for these without one, the product refuses with EXECUTION_SOURCE_REQUIRED and tells you to create and activate a twin. That is the intended answer, not a failure.
Create an admitted twin
In the console, open Twins, select Create admitted twin, then Activate numerical model.
From the terminal, attach a shell to the running platform and admit a bundle:
livemore attach
twin admit <bundle.json>
twin activate <twin-id> version=<n>
Exactly one twin is authoritative at a time, across Atlas, LIFE Patch, Cendos, the terminal and notebooks.
Next: learn the terminal commands or try the worked examples.
Questions about this page?
Email us